nanology.us Site Map
Pages
- About
- BIO CEO 2019: Reshaping Tumor Microenvironments via Immunotherapies
- Contact
- Development
- HOME
- Immune Response
- Legal
- NanOlogy in the News
- NanOlogy.us Cookie Policy
- News
- Presentations
- Press Releases
- Publications
- Site Map
- Technology
- Video: Highlights of NanoPac® Injection for Pancreatic Cancer
- Video: NanoPac® Injection for Pancreatic Cancer
Posts by category
- Category: Home Page
- NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
- NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
- Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
- Pancreas: Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel – Initial Report of Safety and Clinical Outcome
- AACR Pancreatic Cancer 2023 Poster: EUS-guided Local Administration of Large Surface Area Microparticle Paclitaxel with Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cncer: A Single Center Experience
- AACR Pancreatic Cancer 2023 Poster: Enhancing the Immune Response in Locally Advanced Pancreatic Cancer (LAPC) with Intratumoral Endoscopic Ultrasound-guided Fine Needle Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX)
- NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
- NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs
- NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
- NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
- NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
- Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
- Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
- Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
- NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
- NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
- Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies
- NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer
- Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery
- NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
- Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood
- NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas
- Video: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (7-minute version)
- ACG 2019 Poster: NanoPac-2017-01 Mid-Study Report: Safety, Tolerability and Preliminary Efficacy of Intracyctic Submicron Particle Paclitaxel (SPP) for the Treatment of Pancreatic Mucinous Cysts
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer
- NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer
- BIOCEO19 Video: Reshaping Tumor Microenvironments via Immunotherapies. Panel including Gere diZerega, MD, Chief Medical Officer of NanOlogy
- ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts
- NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
- Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
- Category: NanOlogy Events
- Category: NanOlogy in the News
- OncLive: LSAM-PTX Demonstrates Disease Control, Safety in Locally Advanced Pancreatic Cancer
- OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
- Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
- JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
- Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
- Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
- Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
- Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug
- Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer
- BioCentury: Tiny Taxanes – How Nanology’s Particle Production Technology Created Submicron Chemotherapy
- Drug Delivery: NanOlogy looks to transform chemotherapy with localized delivery platform
- Drug Development: NanOlogy Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery
- DermWire: NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases
- Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference
- PharmaVOICE: Next-Generation Nanomedicines
- Drug Delivery Business: NanOlogy takes nanoparticle tech into Phase II trials
- Clinical Leader: Trial Aims To Kill Cancer Without Chemotherapy Side Effects
- DDNEWS: New Cancer Answer
- Ovarian Cancer News: First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery
- Journal for Clinical Studies: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
- Drug Delivery: NanOlogy takes nanoparticle tech into phase 2 trials.
- PBR: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
- Practical Dermatology: Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AK
- DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
- Cancer Treatment: DFB Pharmaceuticals forms new company that could revolutionize cancer treatment
- ‘Bare’-ish on naked effort, Nanology unveils particle approach across cancers
- DFB Pharmaceuticals Forms NanOlogy™
- DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
- Category: NanOlogy Press Release
- NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts
- NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®
- NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site
- NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®
- NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response
- NanOlogy to Present Positive Preclinical Data for NanoDoce® in Treatment of Uro-Oncologic Cancers at 2019 Genitourinary Cancers (ASCO-GU) Symposium
- NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference
- Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery
- DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis
- NanOlogy Adds Clinical Trial Sites for Phase 2 Clinical Trials of NanoPac® in Pancreatic Cancer and Pancreatic Mucinous Cysts
- NanOlogy to Unveil Positive Preclinical Data for Inhaled NanoPac® in Treatment of Lung Cancer at 2018 ASCO Annual Meeting
- NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
- NanOlogy to Present Abstract on Preclinical Study of Nebulized NanoPac for Lung Cancer at 2018 ASCO Annual Meeting
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial for Cutaneous Metastases and DFB Soria Provides an Update on AK Trial
- NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference
- NanOlogy to Present Update on Cancer Treatment Clinical Program at Biotech Showcase in San Francisco
- NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac® Adding to Trials in Prostate and Ovarian Cancers
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
- NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Ovarian Cancer
- DFB Soria Gives Update on Enrollment in Phase 2 Clinical Trial of SOR007 (Nanoparticle Paclitaxel) Ointment for Actinic Keratosis (AK)
- DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
- Category: Presentations
- SITC 2023 Poster: Local Administration of Large Surface Area Microparticle Docetaxel is Associated with Anti-tumor Immunomodulation Across Multiple Tumor Types
- ASCO 2023 Abstract: Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies
- DDW 2023 Poster: Intracystic Injection of Large Surface Area Microparticle Paclitael for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol
- NanOlogy General Presentation (January 2023)
- DDW 2022 Poster: The Efficacy of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (NanoPac®) in the Management of Intraductal Papillary Mucinous Neoplasms: Results from an Expanded Access Protocol
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac)
- DDW 2021 Poster: Tandem EUS-Guided Fine Needle Injection of Intracystic Submicron Particle Paclitaxel (Nanopac®) as a Treatment for Branch-Duct IPMN: Safety, Pharmacokinetic, and Preliminary Efficiency
- SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases
- ASCO 2020 Abstract: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery
- Digestive Disease Week 2020: Intracystic Injection of Submicron Particle Paclitaxel (SPP) for the Treatment of Mucinous Pancreatic Cystic Lesions Resulted in Reduction in Cyst Volume, an Interim Report (Mohamed O. Othman)
- Digestive Disease Week 2020: EUS-guided Injection of Intratumoral Submicron Particle Paclitaxel (SPP) for the Treatment of Locally Advanced Pancreatic Adenocarcinoma (LAPC) – Phase 2 Study (Neil Sharma, MD)
- Video Highlights: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (3-minute version)
- ACG 2019 Plenary Presentation: A Novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer.
- ATS 2019 Poster: Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel
- SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases
- ASCO 2018 Poster: NanoPac Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model
- Category: Publications
- Journal for ImmunoTherapy of Cancer: Local Administration of Large Surface Area Microparticle Docetaxel is Associated with Anti-tumor Immunomodulation Across Multiple Tumor Types
- Cancers: The Role of Therapeutic Endoscopic Ultrasound in Pancreatic Cancer: An Endoscopic Oncologists Perspective
- Diagnostics: A Review of Endoscopic Ultrasound-Guided Chemoablative Techniques for Pancreatic Cystic Lesions
- Diagnostics: Pancreatic Cystic Neoplasms: Diagnosis and Management
- Endosc Int Open: Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cystsEarly phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts
- The Journal of Urology: Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer
- Drug Delivery and Translational Research: Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies
- Respiratory Drug Delivery: Aggregated High Surface Area Particle Technology for Pulmonary Drug Delivery
- Endoscopic Ultrasound: An Update on EUS-Guided Ablative Techniques for Pancreatic Cyctic Lesions
- Breast Cancer Research & Treatment: Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer
- Cancers 2019: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model
- Cancer Chemotherapy & Pharmacology: Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies
- Category: Soria
- Category: Uncategorized
